Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Key Takeaways One shot a month of an experimental drug yielded promising results in a new clinical trialThe drug, called ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

A new trial has found that a weight loss drug taken monthly helps people to lose 20 percent of their body weight. Other weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...